Equillium, Inc. (EQ) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Equillium, Inc.
Address
2223 Avenida De La Playa
La Jolla, CA 92037
United States of America (the)
Phone
858 412 5302
Website
Sector
Healthcare
Industry
Biotechnology
Employees
14
First IPO Date
October 12, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Bruce D. Steel | Co-Founder, Chief Executive Officer & Director | 1.23M | 1966 |
| Christine Zedelmayer | Senior Vice President & Chief Operating Officer | 810,292 | 1970 |
| Stephen Connelly | Chief Scientific Officer & President | 926,562 | 1981 |
| Snehal Naik | Chief Development Officer | 0 | N/A |
| Lisette Acevedo | Vice President of Clinical Development | 0 | N/A |
| Penny Tom | Senior Vice President of Finance & Principal Accounting Officer | 0 | N/A |
| Michael Moore | Vice President of Investor Relations & Corporate Communications | 0 | N/A |
Description
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
